))
Taking Aim at MET and KRAS in NSCLC
Manage episode 407462012 series 3560609
Content provided by Jacqueline Stone and OBR Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and OBR Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Tejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targeted therapies for non-small cell lung cancer (NSCLC), particularly tepotinib (Tepmetko) for MET exon 14 and sotorasib (Lumakras) for KRAS G12C. The MET exon 14 skip mutation has attracted renewed attention because tepotinib and capmatinib (Tabrecta), which both target this mutation, recently received FDA approvals. But MET can be disrupted in other ways, as well. Listen as Dr. Patil discusses the different types of MET alterations, how to identify MET activation in patients, and best practices for using tepotinib to treat MET activation that arises as a resistance mechanism to the EGFR inhibitor osimertinib (Tagrisso).
111 episodes
Share
